Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan-Willem Alffenaar

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Clinical Pharmacology and Therapeutics|May 6, 2025
Gut Microbiota in Patients with Tuberculosis Associated with Different Drug Exposures of Antituberculosis DrugsYue Zhu, Qiao Liu, Jan-Willem Alffenaar, et al.
Open Forum Infectious Diseases|October 9, 2025
Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysisAndrea Llamas-Lopez, James A Seddon, Felicia C Chow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 24, 2024
Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From ChinaYue Zhu, Lina Davies Forsman, Cheng Chen, et al.
BMJ Open|April 29, 2021
Protocol for establishing an Adaptive Diseases control Expert Programme in Tanzania (ADEPT) for integrating care of communicable and non-communicable diseases using tuberculosis and diabetes as a case studyStellah G Mpagama, Kaushik Ramaiya, Troels Lillebæk, et al.
International Journal of Antimicrobial Agents|September 28, 2020
Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practicesSahand Imani, Jan-Willem Alffenaar, Menino O Cotta, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill PatientsAnne-Grete Märtson, Kim C M van der Elst, Anette Veringa, et al.
The Journal of Infection|July 8, 2026
Evidence for a relationship between concentrations of nucleos/tide analogue agents and treatment outcome in chronic hepatitis B infection: A systematic reviewGloria Sukali, Motswedi Anderson, Khadija Said Mohammed, et al.
Pathogens (Basel, Switzerland)|December 31, 2025
Association of Antimicrobial Susceptibility with Treatment Response in <i>Mycobacterium avium complex</i> Pulmonary DiseaseXuejiao Luo, Yuhang Chen, Lina Davies Forsman, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 4, 2024
Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatmentSainan Wang, Lina Davies Forsman, Chunhua Xu, et al.
British Journal of Clinical Pharmacology|July 21, 2021
Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementationIndy Sandaradura, Jan-Willem Alffenaar, Menino O Cotta, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology and Therapeutics|May 6, 2025
Gut Microbiota in Patients with Tuberculosis Associated with Different Drug Exposures of Antituberculosis DrugsYue Zhu, Qiao Liu, Jan-Willem Alffenaar, et al.
Open Forum Infectious Diseases|October 9, 2025
Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysisAndrea Llamas-Lopez, James A Seddon, Felicia C Chow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 24, 2024
Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From ChinaYue Zhu, Lina Davies Forsman, Cheng Chen, et al.
BMJ Open|April 29, 2021
Protocol for establishing an Adaptive Diseases control Expert Programme in Tanzania (ADEPT) for integrating care of communicable and non-communicable diseases using tuberculosis and diabetes as a case studyStellah G Mpagama, Kaushik Ramaiya, Troels Lillebæk, et al.
International Journal of Antimicrobial Agents|September 28, 2020
Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practicesSahand Imani, Jan-Willem Alffenaar, Menino O Cotta, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill PatientsAnne-Grete Märtson, Kim C M van der Elst, Anette Veringa, et al.
The Journal of Infection|July 8, 2026
Evidence for a relationship between concentrations of nucleos/tide analogue agents and treatment outcome in chronic hepatitis B infection: A systematic reviewGloria Sukali, Motswedi Anderson, Khadija Said Mohammed, et al.
Pathogens (Basel, Switzerland)|December 31, 2025
Association of Antimicrobial Susceptibility with Treatment Response in <i>Mycobacterium avium complex</i> Pulmonary DiseaseXuejiao Luo, Yuhang Chen, Lina Davies Forsman, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 4, 2024
Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatmentSainan Wang, Lina Davies Forsman, Chunhua Xu, et al.
British Journal of Clinical Pharmacology|July 21, 2021
Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementationIndy Sandaradura, Jan-Willem Alffenaar, Menino O Cotta, et al.
Pageof 10